Hangzhou Nansu Technology raises Series A for brain-machine interface therapy
What's the deal? Hangzhou Nansu TechnologyDealroom has a profile for this one. Try Dealroom →, a digital medical startup treating speech, hearing, and cognitive disorders, has raised tens of millions of yuan in a Series A round.
Meihua Venture CapitalDealroom has a profile for this one. Try Dealroom → led the round, with Jiangxi Financial Holding GroupDealroom has a profile for this one. Try Dealroom → following on.
The company is based in Hangzhou's Future Sci-Tech City, with a research centre in Shenzhen and a production base in Anji, Huzhou.
Why now? Nansu plans to use the funds to develop its "time-target" closed-loop brain-machine interface platform.
It will also fund clinical validation, regulatory filing, and commercialisation of its combined digital-therapy and electrical-stimulation treatment products.
Its flagship device, Xiaonan Listen-Speak, is billed as the world's first home-based smart rehabilitation tool covering children's core hearing and language training needs.
What could go wrong? Brain-machine interface products face long clinical validation and regulatory approval timelines.
Turning early-stage technology into approved, commercialised products is far from guaranteed, and the remaining funds must also stretch to build out a service network.
The signal: Backing from a state-linked fund alongside a private investor signals that early-stage brain-machine interface therapy is moving from research into a commercial race, with home-based devices like Xiaonan Listen-Speak positioning Nansu beyond the clinic.
Read more: ITjuzi
Image credit: "Elon Musk and the Neuralink Future" by jurvetson is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.
